Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)

NCT05607420 is registered in ClinicalTrials.gov with Cellectis S.A. as lead sponsor.

NCT NCT05607420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05607420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)
Lead sponsor
Cellectis S.A.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 1, 2022
Completion date
August 31, 2027
Enrollment
80 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma (b-nhl)